INTF - ETF AI Analysis
Top Page
iShares MSCI Intl Multifactor ETF (INTF)
Rating:64Neutral
Price Target:―
Positive Factors
Broad International Diversification
The fund spreads its investments across many countries, with meaningful exposure to Japan, the UK, and several major European markets, which helps reduce reliance on any single economy.
Balanced Sector Mix
Holdings are spread across financials, industrials, consumer, technology, health care, and other sectors, helping to cushion the impact if one industry struggles.
Competitive Expense Ratio
The ETF charges a relatively low fee, so less of your potential return is lost to ongoing costs.
Negative Factors
Heavy Tilt Toward Financials
Financial stocks make up a large share of the portfolio, which can increase sensitivity to interest rate changes and banking sector stress.
Mixed Performance Among Top Holdings
While some major positions like ASML and Mitsubishi UFJ have shown strong gains, others such as Nestlé, Royal Bank of Canada, and AstraZeneca have been weaker, creating uneven contribution to returns.
Limited U.S. Market Exposure
The fund has only a small allocation to U.S. stocks, so investors who want significant exposure to the U.S. market would need to pair this ETF with other holdings.
INTF vs. SPDR S&P 500 ETF (SPY)
AUM3.21B
RegionDeveloped Markets
Expense Ratio0.16%
Beta0.75
IssueriShares
Inception DateApr 28, 2015
Dividend Yield2.75%
Asset ClassEquity
Index TrackedSTOXX International Equity Factor
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume356,477
30 Day Avg. Volume256,562
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
45.71Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering472
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
INTF Summary
INTF is the iShares MSCI Intl Multifactor ETF, which follows the STOXX International Equity Factor index. It invests in a wide mix of companies outside the U.S., with big exposure to countries like Japan, the UK, and France, and sectors such as financials and industrials. Well-known holdings include Novartis and ASML. The fund uses a rules-based approach to pick stocks it sees as higher quality or better value, which may help with long-term growth and diversification beyond the U.S. stock market. A key risk is that international stocks can be volatile and are affected by currency and global economic swings.
How much will it cost me?The iShares MSCI Intl Multifactor ETF (INTF) has an expense ratio of 0.16%, which means you’ll pay $1.60 per year for every $1,000 invested. This is lower than average because it’s passively managed, focusing on tracking a multifactor index rather than active stock selection.
What would affect this ETF?The iShares MSCI Intl Multifactor ETF (INTF) could benefit from growth in developed markets outside the U.S., especially if sectors like financials and technology perform well, as they make up a significant portion of the fund. However, challenges such as rising interest rates or economic slowdowns in these regions could negatively impact key holdings like Novartis and ASML, as well as broader sector performance. Regulatory changes or geopolitical tensions in developed markets may also influence the ETF's future returns.
INTF Top 10 Holdings
INTF leans heavily on non-U.S. blue chips, with Europe and other developed markets outside the U.S. doing most of the talking. ASML and ABB have been the fund’s main engines, with momentum that’s helped offset weakness elsewhere. On the flip side, big health care names like Roche and Novartis have been losing steam lately, while Nestlé has been more of a steady but uninspiring ballast. Financials such as Royal Bank of Canada and HSBC add a clear banking tilt, but their recent lagging performance has slightly weighed on the fund.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novartis AG | 2.25% | $68.12M | CHF224.37B | 26.94% | 80 Outperform | |
| ASML Holding NV | 2.08% | $62.84M | €453.65B | 92.32% | 76 Outperform | |
| Roche Holding AG | 1.06% | $32.20M | $319.34B | 22.67% | 73 Outperform | |
| Royal Bank Of Canada | 1.03% | $31.04M | $228.12B | 42.45% | 75 Outperform | |
| AstraZeneca | 1.02% | $30.94M | $308.91B | 33.79% | 80 Outperform | |
| Nestlé SA | 1.01% | $30.62M | CHF198.27B | -3.88% | 71 Outperform | |
| HSBC Holdings | 0.94% | $28.30M | £221.08B | 45.71% | 80 Outperform | |
| ABB Ltd | 0.93% | $27.99M | CHF120.70B | 45.96% | 78 Outperform | |
| TotalEnergies SE | 0.86% | $26.12M | €165.90B | 30.75% | 78 Outperform | |
| BHP Group Ltd | 0.86% | $25.89M | AU$266.91B | 54.88% | 68 Neutral |
INTF Technical Analysis
Positive
―
Price Trends
39.84
Negative
38.55
Positive
36.64
Positive
Market Momentum
-0.29
Negative
52.23
Neutral
88.72
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For INTF, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 38.70, equal to the 50-day MA of 39.84, and equal to the 200-day MA of 36.64, indicating a neutral trend. The MACD of -0.29 indicates Negative momentum. The RSI at 52.23 is Neutral, neither overbought nor oversold. The STOCH value of 88.72 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INTF.
INTF Peer Comparison
Comparison Results
Performance Comparison
INTF
iShares MSCI Intl Multifactor ETF
39.35
12.40
46.01%
GSIE
Goldman Sachs ActiveBeta International Equity ETF
―
―
―
LVHI
Legg Mason International Low Volatility High Dividend ETF
―
―
―
IMTM
iShares MSCI Intl Momentum Factor ETF
―
―
―
IDMO
Invesco S&P International Developed Momentum ETF
―
―
―
PXF
Invesco FTSE RAFI Developed Markets ex-U.S. ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents